Retrospective analysis of clinical features of pembrolizumab induced psoriasis [0.03%]
派姆单抗诱导的银屑病临床特征的回顾性分析
Ming Shu,Zhiqiang Fan,Bin Huang et al.
Ming Shu et al.
To explore the clinical features of pembrolizumab induced psoriasis to provide reference for the optimal treatment of immune checkpoint inhibitor-induced psoriasis. Clinical reports of pembrolizumab induced psoriasis were collected by searc...
Navigating antibody‒drug conjugates (ADCs): from metastatic to early breast cancer treatment strategies [0.03%]
抗体-药物偶联物(ADC)治疗乳腺癌的策略：从晚期到早期
Tala Najdi,Lea Awad,Antoine Chartouni et al.
Tala Najdi et al.
We are currently living in the era of precision medicine, and antibody‒drug conjugates (ADCs) represent promising advancements in targeted cancer therapy. While several ADCs have been investigated over the years, only three have gained FDA...
Discovery of potent CRBN-recruiting epidermal growth factor receptor (EGFR) degraders in vitro [0.03%]
体外高效CRBN募集型表皮生长因子受体（EGFR）降解剂的发现
Wenbo Hu,Jinmei He,Tianyu Xie et al.
Wenbo Hu et al.
Epidermal Growth Factor Receptor (EGFR), a transmembrane receptor tyrosine kinase (RTK) belonging to the ErbB family, initiates cancer-promoting pathways upon binding with epidermal growth factor (EGF). This activation leads to increased ce...
Does anamorelin have beneficial effects in advanced cancer patients with systemic inflammation in the real world? [0.03%]
安莫雷林对真实世界晚期癌症全身性炎性患者的获益作用分析
Koji Amano,Tateaki Naito,Vickie E Baracos
Koji Amano
Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity [0.03%]
HP518（一种PROTAC AR降解剂）治疗mCRPC患者的Ⅰ期临床研究：安全性、药代动力学及抗肿瘤活性结果分析
Arun A Azad,Howard Gurney,Craig Underhill et al.
Arun A Azad et al.
HP518 is an oral PROteolysis TArgeting Chimera (PROTAC) protein degrader targeting the wild-type androgen receptor (WT-AR) and mutant AR ligand-binding domain (AR-LBD). A multicenter, first-in-human, open-label Phase 1 dose escalation study...
Glasdegib combined with chemotherapy in the treatment of patients with acute myeloid leukemia: a comprehensive meta-analysis [0.03%]
glasdegib联合化疗治疗急性髓系白血病患者的研究：一项荟萃分析
Abdelaziz A Awad,Ahmed Yasser Shaban,Fatma Mohammed et al.
Abdelaziz A Awad et al.
Background: Acute myeloid leukemia (AML) is characterized by clonal expansion of myeloid precursors, often accompanied by poor prognostic outcomes in older populations due to molecular heterogeneity and resistance to conv...
MLN0905, a new inhibitor of Polo-like kinase 1 (PLK1), enhances the efficiency of lenalidomide in promoting the apoptosis of multiple myeloma cell lines [0.03%]
新型 polo 样激酶 1(PLK1) 抑制剂 MLN0905 可增强来那度胺对多发性骨髓瘤细胞系促凋亡作用的效率
Reyhane Piri,Minoo Shahidi,Zahra Pooraskari et al.
Reyhane Piri et al.
Multiple myeloma (MM) is a prevalent bone marrow cancer that often presents challenges due to treatment resistance. This study assessed the apoptotic and antiproliferative effects of the Polo-like kinase 1 inhibitor MLN0905, alone and in co...
PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancreatic cancer [0.03%]
PANTAX Ⅰb期临床试验：外排泵抑制剂SCO-101联合吉西他滨和白蛋白结合型紫杉醇治疗不可切除或转移性胰腺癌的研究
Susy Shim,Anke Reinacher-Schick,Anna-Lena Kraeft et al.
Susy Shim et al.
De novo or acquired resistance to chemotherapy is ubiquitous in pancreatic ductal adenocarcinoma (PDAC). SCO-101 is an oral compound that may counteract chemo-resistance by interacting with SRPK1, ABCG2 drug transporter, and liver enzyme UG...
The up-regulated expression level of deubiquitinating enzyme USP46 induces the apoptosis of A549 cells by TRAF6 [0.03%]
去泛素化酶USP46的上调表达通过TRAF6诱导A549细胞凋亡
Xuan Zhao,Yanan Li,Dandan Gu et al.
Xuan Zhao et al.
This study investigates the function of Ubiquitin-specific protease 46 (USP46), a deubiquitinase, in the context of lung cancer, particularly its role in regulating cell proliferation via the ubiquitination of TRAF6. In A549 lung cancer cel...
Patient-derived tumor organoids for cancer immunotherapy: culture techniques and clinical application [0.03%]
基于患者肿瘤类器官的癌症免疫治疗：培养技术与临床应用
Ningning Yao,Na Jing,Jianzhong Lin et al.
Ningning Yao et al.
Cancer immunotherapy has revolutionized tumor treatment. However, robust and effective testing platforms remain lacking, especially for the selection of the optimized therapy at the patient-specific level. Unlike conventional treatment eval...